Surrozen, Inc.
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company discovering and developing antibody-based therapeutics that selectively modulate the Wnt signaling pathway, which is involved in tissue repair and regeneration. Its current focus is ophthalmology, developing treatments for retinal diseases including diabetic… From the company’s description.
In fiscal 2025, Surrozen, Inc. reported revenue of $3.48M, down 67.4% from fiscal 2024, and a net loss of $242.03M. Operations used $30.24M in cash. Over the twelve months to Jun 30, 2026, revenue was $11.51M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Surrozen, Inc. does
In the company’s own words
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company discovering and developing antibody-based therapeutics that selectively modulate the Wnt signaling pathway, which is involved in tissue repair and regeneration. Its current focus is ophthalmology, developing treatments for retinal diseases including diabetic macular edema, wet age-related macular degeneration and uveitic macular edema. Its lead candidates include SZN-8141, which combines Fzd4 agonism with VEGF antagonism, and SZN-8143, which adds IL-6 antagonism; research programs also target retinal and corneal diseases. Surrozen’s SWAP platform designs multispecific antibodies to activate Wnt signaling through selected receptors. The company has one collaboration with Boehringer Ingelheim covering Fzd4 bispecific antibodies, including SZN-413, which Boehringer Ingelheim is responsible for developing, manufacturing and commercializing. Surrozen discontinued development of its liver-focused candidate SZN-043 in 2025 and has no commercialized products described here. It also conducts antibody discovery research for TCGFB targeting TGF-β. Its website is www.surrozen.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1824893
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Surrozen, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Surrozen, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Surrozen, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Surrozen, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Surrozen, Inc.'s last four quarterly filings that the numbers alone won't show?”